Cigna earnings beat by $0.04, revenue topped estimates
ROCKVILLE, MD - MaxCyte Inc. (NASDAQ: MXCT; LSE: MXCT), a cell-engineering company, disclosed that John Johnston, a Non-Executive Director, exercised options for 3,000 shares and subsequently sold them on Monday. The sale occurred at prices ranging from $4.520 to $4.720 per share, according to a filing with the U.S. Securities and Exchange Commission.
Johnston’s transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, set on December 19, 2023, which allows company insiders to sell stocks at a predetermined time to avoid accusations of insider trading. These options were part of those that expire on July 18, 2028.
Following the exercise and sale of the options, Johnston now owns 120,583 shares of MaxCyte’s common stock, representing approximately 0.1% of the company’s issued stock capital. Additionally, he holds 171,918 options over common stock and 21,367 restricted stock units.
The company, known for its ExPERT™ platform and Flow Electroporation® technology, provides platform technologies that support the development of cell-based therapies. MaxCyte’s suite of products includes instruments such as the ATx™, STx™, GTx™, and VLx™, as well as processing assemblies and software protocols.
The options were exercised at a price of $2.932 each, and the aggregate sale price was approximately $4.6445 per share. The transactions took place on the US Stock Exchange, Nasdaq.
This news comes as part of a routine notification of transactions by persons discharging managerial responsibilities within the company. The information is based on a press release statement and provides insight into the financial activities of MaxCyte’s management team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.